Evinacumab
Based on 1 publication(s) in Google Scholar
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.24%
- CAS 番号: 1446419-85-7
- 分子量:144.5 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Evinacumab
More
生物活性
Human IgG4 kappa
Human
ANGPTL3
Evinacumab (25 mg/kg; s.c.; once weekly for 8 weeks) lowers serum TG and cholesterol levels in dyslipidemic C57Bl/6 mice[1].
Evinacumab (10 mg/kg; s.c.; single) lowers serum HDL-C by an EL-dependent mechanism in Lipg-/- mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57Bl/6 mice (8-week-old)[1].
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection, single.
-
Result:Caused a rapid reduction in TG levels with the maximal mean level of serum TG 55% lower than control group, and reduced 26% levels of TC.
Significantly reduced VLDL-TG, VLDL-cholesterol, and HDL-C levels.
Increased postheparin plasma LPL and improved lipid tolerance.
-
Animal Model:Male C57Bl/6 mice (8-week-old; on a high-fat high-cholesterol diet)[1].
-
Dosage:25 mg/kg
-
Administration:Subcutaneous injection, once weekly for 8 weeks.
-
Result:Led to a marked and sustained reduction in circulating TG levels (up to 53%).
Significantly reduced levels of TC (up to 35%) and LDL-C (up to 45%).
-
Animal Model:Lipg-/- mice[1].
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection, single.
-
Result:Blocked the inhibitory action of ANGPTL3 on EL with an IC50 value of 96 nM.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized huANGPTL3-c-his, can bind Evinacumab. The EC50 for this effect is 6.517 ng/mL.
化学情報
-
CAS 番号 1446419-85-7
-
性状 Liquid
-
分子量 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Evinacumab]
-
別名
REGN1500
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
JCI Insight
Angiopoietin-like 8 governs osteoblast-adipocyte lineage commitment during skeletal aging. [Abstract]2025 Oct 21:e189371. PMID: 41118261
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Evinacumab 関連分類
HY-P99194 関連分類
Powered by Bioz